Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec + Irinotecan + Carboplatin in Extensive Stage SCLC
NCT00193349Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2002
- Primary completion
- Dec 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of imatinib in small cell lung cancer (SCLC), sponsored by SCRI Development Innovations. Started Sep 2002; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00193349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193349.